NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 5 July 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Items 4.1.3 to 5.2.2
3. Iftab Akram Present for all items
4. Michael Chambers Present for all items
5. Dr Prithwiraj Das Present for all items
6. Chamkhor Dhillon Present for all items
7. Dr Rob Forsyth Present for all items
8. Dr Pedro Saramago Goncalves Present for all items
9. Dr Natalie Hallas Present for all items
10. John Hampson Present for all items
11. Dr Nigel Langford Items 4.1.3 to 5.1.3
12. Dr Andrea Manca Items 1 to 4.1.3
13. Iain McGowan Present for all items
14. Stella O’Brien Present for all items
15. Professor Matthew Stevenson Present for all items
16. Professor Paul Tappenden Present for all items
17. Dr Derek Ward Present for all items

NICE staff present

Jasdeep Hayre, Associate Director Present for all items

Celia Mayers, Project Manager Present for all items

Louise Crathorne, Heath Technology Assessment Adviser Items 1 to 4.2.2

Christian Griffiths, Heath Technology Assessment Adviser Items 5 to 5.2.2

Catherine Parker, Heath Technology Assessment Analyst Items 1 to 4.2.2

Harsimran Sarpal, Heath Technology Assessment Analyst Items 1 to 4.2.2

Janette Kankam-Boadu, Heath Technology Assessment Analyst Items 5 to 5.2.2

Benjamin Gregory, Business Analyst, RIA Items 4.1.3 to 4.2.2 & 5.1.3 to 5.2.2

Catrin Austin, Technical Analyst, Technical Analyst, Methods, and Economics, Items1 to 4.2.2

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment, Items 1 to 4.2.2

Neha Jiandani, Technical Analyst, Commercial Liaison Items 1 to 4.2.2

Ella Livingstone, Technical Analyst, Commercial Risk Assessment Items 4.1.3 to 4.2.2

Anna Sparshatt, Senior Medical Editor Items 1 to 4.2.2

Hayley Garnett, Senior Medical Editor Items 5 to 5.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 5 to 5.2.2

Catherine Pank, Assistant Project Manager, COT Items 5 to 5.1.3

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Mohammed Towhasir, Administrator, TA Items 1 to 4.2.2

Leah Kelly, Administrator, TA Items 5 to 5.2.2

External assessment group representatives present

Lorna Aucott, Aberdeen HTA Group Items 1 to 4.1.3

Graham Scotland, Aberdeen HTA Group Items 1 to 4.1.3

Gemma Marceniuk, BMJ Group Items 5 to 5.1.3

Victoria Wakefield, BMJ Group Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 4.2.2

Dr Graham Collins, Consultant Haematologist and Lymphoma MDT lead, Clinical expert nominated by Kite, Items 1 to 4.1.3

Dr Tobias Menne, Consultant Haematologist, Clinical expert nominated by RC Physicians, Items 1 to 4.1.3

Professor Winfried Amoaku, Consultant Ophthalmologist & Assoc Professor/Reader in Ophthalmology, Clinical expert nominated by RC Ophthalmologists, Items 5 to 5.1.3

Professor Faruque Ghanchi, Consultant Ophthalmologist, Clinical expert nominated by Abbvie, Items 5 to 5.1.3

Stephen Scowcroft, Patient expert nominated by Macular Society, Items 5 to 5.1.3

Bernadette Warren, Patient expert nominated by Macular Society, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. New committee members Chamkhor Dhillon & Pedro Saramago Goncalves were introduced and welcomed to TA Committee C.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 1 June 2022.

### Appraisal of axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin’s lymphoma [ID1685]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Kite, a Gilead company.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and has helped co-ordinate a (University of Utrecht) training programme in Real World Evidence for Roche, which did not involve consideration of any Roche products. Both Pfizer and Roche are manufacturers of possible comparator therapies. It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared financial interests as he has carried out paid advisory boards with Roche and Novartis in an unrelated area - multiple sclerosis. It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
* Nominated clinical expert Dr Graham Collins declared direct financial interests as he has received honoraria for speaker and advisory work from Kite / Gilead. It was agreed his declaration would not prevent Dr Collins from providing expert advice to the committee.
* Nominated clinical expert Dr Tobias Menne declared direct financial interests as he has received travel grants from Amgen, Jazz, Pfizer, Bayer, Kyowa Kirin, Celgene, Kite/Gilead, Janssen, and Takeda, honoraria for advisory board meetings from Kite/Gilead, Amgen, Novartis, Pfizer, Celgene/BMS, Daiichi Sankyo, Atara, Roche, Janssen, and honoraria for lectures from Kite/Gilead, Takeda, Janssen, Roche, Servier, Novartis, Celgene and Research funding from Janssen, Astra Zeneca, Novartis. It was agreed his declaration would not prevent Dr Menne from providing expert advice to the committee.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Andrea Manca, Dr Rob Forsyth, and Stella O’Brien.
  1. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10578>.

### Appraisal of dexamethasone intravitreal implant for treating diabetic macular oedema in people without a pseudophakic lens [ID3951]

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AbbVie.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and has helped co-ordinate a (University of Utrecht) training programme in Real World Evidence for Roche, which did not involve consideration of any Roche products. Both Pfizer and Roche are manufacturers of possible comparator therapies. It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared financial interests as he has carried out paid advisory boards with Roche and Novartis in an unrelated area - multiple sclerosis. It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
* Nominated clinical expert Professor Winfried Amoaku declared direct financial and non-financial interests as.
* His institution has received funding for research he has participated in sponsored by Allergan, Bausch and Lomb, Novartis, Pfizer, and Roche.
* He has served on advisory boards and received honoraria from Abbvie, Alcon, Allergan, Bayer, Novartis, Pfizer, Roche, Apellis, Biogen, and Teva Pharma
* He has advised Roche on current and potential future Treatment Pathways for Geographic Atrophy.
* He has received Educational Travel Grants from Alimera, Allergan, Bayer, Novartis, and Pfizer.
* He is a member of the Data & Safety Monitoring Board, and several Trial Steering Committees. It was agreed his declaration would not prevent Professor Amoaku from providing expert advice to the committee.
* Nominated clinical expert Professor Faruque Ghanchi declared direct financial and non-financial interests as he has provided consultancy work for Abbvie/Allergan, Alimera(past), Novartis and Roche, and he has an academic interest in diabetic retinopathy, involved in clinical research on new therapeutic agents. It was agreed his declaration would not prevent Professor Ghanchi from providing expert advice to the committee.
* Nominated patient expert Stephen Scowcroft declared indirect financial interests as Macular Society receive financial support from a variety of pharma companies, none have any direct editorial input into our information/ activities. It was agreed his declaration would not prevent Stephen from providing expert advice to the committee
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Michael Chambers, Iain McGowan, and Stella O’Brien
  1. Part 2 – Closed session (company representatives, experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10889>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 2 August 2022 and will start promptly at 09:30.